The full results of the asthma part of the GlaxoSmithKline PLC’s Salford Lung Study have confirmed the beneficial effects of the once-daily inhaler combination Relvar Ellipta (fluticasone furoate/vilanterol, known as Breo Ellipta in the US) on asthma symptoms compared with usual care, in a “real-world” clinical effectiveness study that calls into question the dominance of double-blind randomized efficacy studies in supporting clinical guidelines and prescribing decisions that drive medicines’ market share and, ultimately, company profits.
The lead investigator for the Salford Lung Study, Ashley Woodcock, professor of respiratory medicine at the University of Manchester, has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?